Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.

Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.

Mult Scler. 2012 Feb;18(2):143-52. doi: 10.1177/1352458511435105. Review.

PMID:
22312009
2.

Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.

Hunt D, Giovannoni G.

Pract Neurol. 2012 Feb;12(1):25-35. doi: 10.1136/practneurol-2011-000092. Review.

PMID:
22258169
3.

Natalizumab: risk stratification of individual patients with multiple sclerosis.

Tur C, Montalban X.

CNS Drugs. 2014 Jul;28(7):641-8. doi: 10.1007/s40263-014-0168-0. Review.

PMID:
24942634
4.

Review of progressive multifocal leukoencephalopathy and natalizumab.

Aksamit AJ.

Neurologist. 2006 Nov;12(6):293-8. Review.

PMID:
17122725
5.

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A.

Lancet Neurol. 2010 Apr;9(4):438-46. doi: 10.1016/S1474-4422(10)70028-4. Review. Erratum in: Lancet Neurol. 2010 May;9(5):463. DeLuca, Andrea [corrected to De Luca, Andrea].

PMID:
20298967
6.

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.

Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.

JAMA Neurol. 2013 Mar 1;70(3):398-402. doi: 10.1001/jamaneurol.2013.1960. Review.

PMID:
23338729
7.

Advances in the management of PML: focus on natalizumab.

Fox R.

Cleve Clin J Med. 2011 Nov;78 Suppl 2:S33-7. doi: 10.3949/ccjm.78.s2.08. Review. Erratum in: Cleve Clin J Med. 2012 May;79(5):312.

8.

Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.

Baldwin KJ, Hogg JP.

Curr Opin Neurol. 2013 Jun;26(3):318-23. doi: 10.1097/WCO.0b013e328360279f. Review.

PMID:
23493158
9.

[[Natalizumab therapy, 2013].

Karácsony M, Bencsik K, Vécsei L.

Ideggyogy Sz. 2014 Jul 30;67(7-8):220-8. Review. Hungarian.

PMID:
25509362
10.

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.

Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Tervaert JW, Nash RA, Hartung HP, Kieseier BC, Racke MM, Frohman EM, Hemmer B.

Arch Neurol. 2007 Feb;64(2):169-76. Review.

PMID:
17296831
11.
12.

The link between VLA-4 and JC virus reactivation.

Monaco MC, Major EO.

Expert Rev Clin Immunol. 2012 Jan;8(1):63-72. doi: 10.1586/eci.11.85. Review.

PMID:
22149341
13.

Progressive multifocal leukoencephalopathy and natalizumab.

Hellwig K, Gold R.

J Neurol. 2011 Nov;258(11):1920-8. doi: 10.1007/s00415-011-6116-8. Epub 2011 Jun 7. Review.

PMID:
21647730
14.

JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?

Diotti RA, Nakanishi A, Clementi N, Mancini N, Criscuolo E, Solforosi L, Clementi M.

Clin Dev Immunol. 2013;2013:967581. doi: 10.1155/2013/967581. Epub 2013 Jun 25. Review.

15.

Natalizumab therapy for multiple sclerosis.

Derfuss T, Kuhle J, Lindberg R, Kappos L.

Semin Neurol. 2013 Feb;33(1):26-36. doi: 10.1055/s-0033-1343793. Epub 2013 May 25. Review.

PMID:
23709210
16.

Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.

Serana F, Chiarini M, Sottini A, Bertoli D, Giustini V, Tessitore MV, Caimi L, Capra R, Imberti L.

J Neuroimmunol. 2014 Dec 15;277(1-2):6-12. doi: 10.1016/j.jneuroim.2014.10.011. Epub 2014 Nov 3. Review.

PMID:
25468273
17.

Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.

Rossi F, Newsome SD, Viscidi R.

Mol Cell Probes. 2015 Feb;29(1):54-62. doi: 10.1016/j.mcp.2014.11.007. Epub 2014 Dec 5. Review.

PMID:
25483260
18.

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA.

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):117-25. doi: 10.1136/jnnp-2015-311100. Epub 2015 Oct 22. Review.

19.

Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.

Gupta S, Weinstock-Guttman B.

Expert Opin Biol Ther. 2014 Jan;14(1):115-26. doi: 10.1517/14712598.2014.864634. Epub 2013 Dec 2. Review.

PMID:
24289270
20.

Natalizumab: bench to bedside and beyond.

Rudick R, Polman C, Clifford D, Miller D, Steinman L.

JAMA Neurol. 2013 Feb;70(2):172-82. doi: 10.1001/jamaneurol.2013.598. Review.

PMID:
23128399
Items per page

Supplemental Content

Write to the Help Desk